Igor Samatoshenkov | Medicine | Best Researcher Award

Mr. Igor Samatoshenkov | Medicine | Best Researcher Award

Vascular surgeon, Uniclinic Brandenburg, Medical school Brandenburg, Germany

Dr. Samatoshenkov Igor Valeryevich  is an accomplished cardiovascular surgeon, innovator, and medical entrepreneur, currently based in Brandenburg, Germany. With an MD and PhD in medical sciences, he has made significant strides in the fields of vascular surgery, regenerative medicine, and gene therapy. He is the founder and CEO of “Angiolife,” a Skolkovo-based biotech company pioneering gene-drug research. As a dedicated academic and clinical expert, Dr. Samatoshenkov has been actively involved in cutting-edge surgical practice, scientific research, and medical education. 🧬💉

Publication Profile

Scopus

ORCID

🎓 Education Background

Dr. Samatoshenkov earned his PhD in 2021 from Kazan Federal University 🎓. His earlier training includes a medical degree from Kazan State Medical University (2009–2015), where he also specialized as a professional medical translator (2012–2014). He pursued advanced phlebology training in endovenous laser obliteration in 2018 in Moscow. His comprehensive education has built a solid foundation for his clinical and research pursuits. 📚🩺

💼 Professional Experience

Dr. Samatoshenkov has over a decade of experience in cardiovascular surgery and medical education. Since 2017, he has been serving in the Department of Cardiosurgery No. 1 and is a graduate student in the Department of Histology, Cytology, and Embryology. From 2015 to 2017, he was an attending physician in the Department of Heart Surgery at the ICDC. He also contributed to academia as an assistant in the Department of Normal Anatomy (2016–2017) and led several student scientific circles from 2011 to 2014. In 2018, he founded “Angiolife,” advancing gene-based therapeutics. 🏥💡

🏆 Awards and Honors

Dr. Samatoshenkov’s innovations have been widely recognized. He won the 2023 National Competition of Innovative Ideas in Medicine by AMTEC Foundation 🏅 and the “Top 50 Innovative Ideas” contest in Tatarstan 🥇. He was a finalist in the 2022 MEDLEADS competition and ranked 2nd in the 2021 All-Russian Intellectual Property contest “Intellect.” He also received accolades from the Academy of Sciences of Tatarstan (2020) and Innopolis Startup Tour (3rd place). 🌟🔬

🔬 Research Focus

Dr. Samatoshenkov’s research spans cardiovascular regeneration, gene and stem cell therapy, and surgical innovation. His pioneering studies in VEGF, ANG, and GDNF gene delivery have opened promising avenues in post-ischemic tissue recovery. His experimental models and cell-mediated delivery techniques are pushing the boundaries of modern medicine. 🧪🧠

🔚 Conclusion

With an exceptional blend of clinical excellence, scientific ingenuity, and entrepreneurial vision, Dr. Igor Samatoshenkov is a leading figure in cardiovascular innovation and regenerative therapy. His mission continues to bridge advanced research with real-world patient solutions. 🌐

📘 Top Publications

  1. Modeling of acute venous lesion of the lower extremities in experiment (2016) – Clinical and Experimental Surgery
    Authors: I.V. Samatoshenkov, B.M. Mirolyubov
    Cited by: —
    Journal Link: Not publicly available online

  2. Effects of direct and indirect delivery of the VEGF gene by cord blood cells to the area of limb ischemia in rats (2017) – Morphological Statements
    Authors: I.V. Samatoshenkov, S.A. Andreev, N.V. Boychuk
    🔗 https://doi.org/10.20340/mv-mn.2017(25).4.14-17
    Cited by: 5+

  3. Comparison of the effectiveness of stimulating angiogenesis in ischemic limbs… (2019) – Creative Cardiology
    Authors: I.V. Samatoshenkov et al.
    🔗 https://doi.org/10.24022/1997-3187-2019-13-3-250-262
    Cited by: 10+

  4. Stimulation of angiogenesis of rat skeletal muscle… (2020) – Morphology
    🔗 https://doi.org/10.34922/AE.2020.157.1.006
    Cited by: 15+

  5. Adenoviral vector delivery of VEGF, angiogenin, and GDNF genes promotes angiogenesis… (2020) – BioNanoScience
    Authors: I.V. Samatoshenkov et al.
    🔗 https://doi.org/10.1007/s12668-019-00688-y
    Cited by: 25+

  6. New experimental model of hind limb ischemia in pot-bellied pigs (2023) – Microvascular Research
    Authors: Igor Samatoshenkov et al.
    🔗 https://doi.org/10.1016/j.mvr.2022.104425
    Cited by: 8+

  7. Combined delivery of the VEGF, ANG, and GDNF genes stimulates angiogenesis and post-ischemic regeneration (2024) – Current Issues in Molecular Biology
    🔗 https://doi.org/10.3390/cimb46080507
    Cited by: 12+

 

Dr. Doljinsuren Enkhbayar | Biomedical Engineering | Best Researcher Award

Dr. Doljinsuren Enkhbayar | Biomedical Engineering | Best Researcher Award

Ph.D candidate, Department of Biomedical Engineering, Yonsei University, South Korea

Doljinsuren Enkhbayar is a dedicated biomedical engineer specializing in AI-driven healthcare solutions and biomedical signal processing. Born in Ulaanbaatar, Mongolia, she has a strong background in medical equipment engineering and biomedical data science. With years of experience in both academic research and clinical applications, she is currently pursuing her Ph.D. in Biomedical Engineering at Yonsei University, South Korea. Her passion lies in wearable health technology, biosensors, and the integration of machine learning in medical diagnostics.

Publication Profile

Google Scholar

🎓 Education

Doljinsuren’s academic journey began at the Mongolian University of Science and Technology, where she earned a Bachelor of Engineering in Medical Equipment and Aircraft Maintenance Engineering. She further advanced her expertise with a Master of Science in Biomedical Engineering from the same university. Currently, she is a Ph.D. candidate at Yonsei University, South Korea, focusing on AI and machine learning applications in biomedical sciences.

💼 Experience

With a strong foundation in biomedical engineering, Doljinsuren has worked as a Biomedical Engineer at the National Center of Maternal and Child Health of Mongolia, where she specialized in medical equipment management and safety assessments. She later served as a Training Master in the Department of Electrotechnique at the Mongolian University of Science and Technology, contributing to research and mentoring students. Additionally, she played a pivotal role as a secretariat member of the Mongolian Society of Biomedical Engineering, advocating for technological advancements in healthcare.

🏆 Awards and Honors

Doljinsuren has received multiple accolades for her research excellence. She was awarded the Best Paper Award by the Mongolian Young Scientist Association (2022) for her study on electrosurgical unit output power measurement. She also gained international recognition for her work on predicting esophageal varices using platelet count/spleen size ratio, presented at Chulalongkorn University, Thailand (2020). Her research on chronic hepatitis C treatment was featured at Liver Week 2019 in Busan, Korea.

🔬 Research Focus

Her research interests revolve around AI in healthcare, biomedical signal processing, wearable health technologies, and biosensors. She actively explores how machine learning and biomedical data science can enhance diagnostics, patient monitoring, and medical device performance. Her contributions to biomaterials research, particularly chitosan-based sustainable packaging, reflect her interdisciplinary expertise in biomedical applications.

🔍 Conclusion

Doljinsuren Enkhbayar is a rising expert in biomedical engineering and AI-driven healthcare innovations. Her interdisciplinary research, coupled with her clinical and academic experience, positions her at the forefront of modern medical technology advancements. With an unwavering commitment to improving healthcare outcomes through AI and biomedical data science, she continues to push the boundaries of innovation and research excellence.

📚 Publications

Explainable Artificial Intelligence Models for Predicting Depression Based on Polysomnographic Phenotypes – Published in Bioengineering (2025). Read Here

Chitosan Extracted from the Biomass of Tenebrio molitor Larvae as a Sustainable Packaging Film – Published in Materials (2024). Read Here

Oral Administration of Hydrolysed Casein-Based Supplements on Chronic Liver Disease Patients – Published in The Liver Week (2020). Read Here

Significant Effect of Lifestyle Modification Intervention in Patients with Newly Diagnosed Type 2 Diabetes – Published in The Liver Week (2017). Read Here